Author: Mokhtar

Aclarion Announces Signing of Commercial Agreement with Porter Hospital, an AdventHealth Facility, to Bring Nociscan Technology to Denver

Porter Hospital becomes first facility in Denver to give patients with chronic low back pain access to revolutionary Nociscan technology that measures biomarkers to pinpoint the source of pain

George Frey, MD becomes the first Aclarion KOL surgeon to use in-hospital MRI to add Nociscan data to his treatment decision process for patients with chronic low back pain

Published clinical data shows that patient outcomes improve and costs decrease when surgical treatment is consistent with disc levels that Nociscan identifies as painful

BROOMFIELD, CO, October 25, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that uses biomarkers and proprietary enhanced intelligence algorithms to help physicians identify the location of chronic low back pain, today announced their expanded presence in Colorado with AdventHealth Porter. From their Denver location, AdventHealth Porter provides exceptional medical care to patients throughout Colorado’s frontline region.

George Frey MD, orthopedic surgeon and founder of the Colorado Comprehensive Spine Institute said, “Treating patients effectively starts with an informed understanding of where their pain comes from. In my experience with Nociscan, objectively measuring the biomarker content associated with pain in an intervertebral disc that may look healthy on an MRI adds to my knowledge of how to treat that patient. At AdventHealth Porter, we strive to provide cost-effective care of the highest quality. The published evidence makes it clear to me that adding Nociscan to our diagnostic evaluation can help us do just that.”

Brent Ness, CEO of Aclarion, said: “In line with our strategy to bring Nociscan to a standard of care through KOL advocacy, we applaud AdventHealth Porter for bringing Nociscan technology to Denver in support of Dr. Frey to use our technology to improve results. while reducing costs. The support of pioneering leaders like Dr. Frey and AdventHealth is exactly the leadership we need to unequivocally demonstrate the superior clinical outcomes for patients that will drive payers’ coverage decisions and provide all patients with access to Nociscan technology. We thank Dr. Frey and AdventHealth look forward to the positive impact that increasing Nociscan volumes will have on the surgical outcomes of chronic low back patients in and around the Denver community.”

“Providing exceptional care with cutting-edge treatments is a core value of our multidisciplinary care team here at AdventHealth Porter,” said Carol Bermingham, Imaging Manager at AdventHealth Porter. “We are excited about adding Nociscan to our MRI capabilities and believe that providing personalized biomarker data to treating physicians is one more investment in our commitment to providing an environment where our physicians can do their very best for their patients . Our radiology service line always strives to stay at the forefront of the technical advancement curve.”

Chronic low back pain (cLBP) is a global healthcare problem, with approximately 266 million people worldwide suffering from degenerative spine disorders and low back pain. It is estimated that low back pain affects approximately 30 million adults in the U.S. population annually, leading to millions of doctor consultations each year.

Aclarion’s proprietary decision support tool, Nociscan, is the first evidence-based SaaS platform that helps physicians non-invasively distinguish between painful and non-painful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to indicate whether a disc may be a source of pain. When combined with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving clinicians clarity to optimize treatment strategies.

About Aclarion, Inc.

Aclarion is a healthcare technology company that uses magnetic resonance spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers and enhanced intelligence algorithms to optimize clinical treatments. The company is entering the chronic low back pain market for the first time with Nociscan, the first evidence-based SaaS platform that helps physicians non-invasively distinguish between painful and non-painful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to indicate whether a disc may be a source of pain. When combined with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving clinicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on management’s current plans and expectations and are subject to a number of uncertainties and risks that could materially affect the company’s current plans and expectations, as well as its future results of operations and financial condition. These and other risks and uncertainties are discussed in more detail in our filings with the Securities and Exchange Commission. Readers are encouraged to read the section entitled “Risk Factors” in the Company’s April 21, 2022 Prospectus as filed with the Securities and Exchange Commission on April 25, 2022 under Rule 424(b)(4), as well as other disclosures. included in the Prospectus and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor contacts:
Kirin M. Smith
PCG Advice, Inc.
646.823.8656
ksmith@pcgadvisory.com

Media contacts:
Jodi Lamberti
SPRIG advice
612.812.7477
jodi@sprigconsulting.com

Source link

October 26, 2023
Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis

In this study, we showed that among the SE alleles, HLA-DRB1*04:05 in particular was strongly associated with the prognosis of ABT treatment. The allele frequency of HLA-DRB1*04:05 in Japanese patients with ACPA-positive RA is reported to be approximately 28%. Because each individual carries two HLA-DRB1 alleles, approximately half of ACPA-positive RA patients have at least one copy of HLA-DRB1*04:05. And HLA-DRB1*04:05 is strongly associated with the development of ACPA-positive RA, with an odds ratio of 5.0²³. HLA, which is innate and unchangeable throughout a person’s life, suggests that the association between HLA and treatment prognosis is not merely coincidental. In other words, the HLA genotype is the cause, which leads to favorable treatment results. Although several associations between the efficacy of SE and ABT have been reported^9,10,11details at the allele level are limited, even though the significance of the specific alleles as potential biomarkers is promising.

In this study, it was found that only HLA-DRB1*04:05 showed an association with response to ABT treatment, while HLA-DRB1*01:01 and 04:10, which share similar SE, showed no significant association. with treatment responsiveness. In addition to the effect of small sample size, the following reasons can be considered. Amino acids at positions 11, 13 and 67 of HLA-DRB1, which are different amino acid sequences than SE, are also involved in the risk of developing RA. Specifically, it was found that in DRB1*04:05 and 04:10, the valine at position 11 is the amino acid most strongly associated with RA sensitivity, while DRB1*01:01 has another amino acid, leucine, at position 11.²⁵. Furthermore, in a study on the risk of developing RA in the Japanese population, it was shown that the risk of RA differs based on the variant of HLA-DRB1, even sharing the same HLA SE allele. It is suggested that HLA-DRB1*01:01, 04:05 and 04:10 are not bioequivalent²³. Furthermore, HLA risk alleles for autoimmune diseases have been reported to significantly influence the pattern of CDR3 sequences in T cell receptors. Furthermore, CDR3 sequences modified by HLA risk alleles have been associated with the recognition of citrullinated antigens. Therefore, sequences other than SE are also believed to be associated with the development and progression of RA and other diseases²⁶.

SE and ACPA-positive RA are strongly associated, and ACPA is also associated with the prognosis of ABT treatment^27,28. Previous reports have also shown that SE is associated with ABT outcomes, even after adjusting for the effect of ACPA^9,10. In this study, both multiple regression analysis and mediation analysis suggested that the effect of the HLA-DRB1*04:05 allele was not an indirect effect mediated by ACPA (Table 4, Figure 2). The impact of SE has been reported to be stronger in ACPA-positive RA than in ACPA-positive non-RA controls^29.30. In other words, SE may be involved in the pathogenesis of RA through mechanisms other than direct effects on ACPA positivity. RA risk HLA is robustly associated with CD4 T cell receptor repertoire⁺ T cells^26.31. RA-sensitive HLA alleles, such as HLA-DRB1*04:05, are associated with autoreactive CD4⁺ T cells, which may be therapeutic targets for ABT.

In this study, methotrexate use was low in the abatacept group. Because in general it has been reported that concurrent use of MTX may not increase the effectiveness of ABT. For example, in a phase III study, ABT did not induce immunogenicity associated with loss of safety or efficacy either with or without MTX³². Also in a retrospective cohort study of RA patients with similar background characteristics who underwent treatment with abatacept, concurrent MTX did not appear to influence clinical outcomes.³³. Based on these findings, we believe that ABT would be a suitable treatment option in daily clinical practice in patients with contraindications to MTX.

In this study, the association between the HLA-DRB1*04:05 allele, an SE allele, and favorable treatment outcomes was significant only in ABT-treated patients, but not in those treated with the IL-6 receptor inhibitor TCZ or a TNF drug. inhibitors. This is consistent with the association between the better prognosis with ABT and SE reported in the Early-AMPLE trial comparing ABT with the TNF inhibitor adalimumab.¹¹. SE was also not strongly associated with the efficacy of the JAK inhibitor tofacitinib¹⁰. These findings may reflect the difference in mechanism of action between ABT, which inhibits costimulation of antigen-presenting cells, and CD4.⁺ T cells and IL-6 receptor inhibitors, TNF inhibitors and JAK inhibitors, which are drugs that block inflammatory cytokine signaling.

There are several limitations to this study. First, due to the retrospective nature of this analysis, we cannot exclude the possibility of selection bias. Second, the number in each treatment group is small, so the effect of HLA alleles with small frequency or small effect size may not have been fully realized. Third, since this study was conducted in a single Japanese cohort and there are ethnic differences in the frequencies of the HLA-DRB1 allele, it is necessary to verify whether the results can be generalized to other cohorts, including other ethnic groups.

In conclusion, we analyzed the association between HLA-DRB1 alleles and prognosis in Japanese patients with RA who initiated treatment with ABT, TCZ, and TNF inhibitors, and we showed that among SE alleles, the HLA-DRB1*04 :05 allele was associated with better outcomes with ABT. This study demonstrates the feasibility of stratifying RA patients based on disease risk HLA alleles and supports the need for a larger prospective study.

Source link

October 26, 2023
New information about bone loss during menopause – better bones
Are you at risk of losing up to 20% of your bone in the years surrounding menopause? Women with accelerated bone loss – dubbed ‘fast losers’ in a new study – are at greater risk of developing osteoporosis and weaker bones than the average woman. The average woman loses only 8-10% of her bone mass during the three years surrounding menopause.

This new research shows there’s an easy way to find out if you’re a “quick loser” of bot so you can take action to stop it.

Find out if you are a “quick loser” of bones

Researchers focused on using the N-telopeptide crosslinks test – a urine test – to help identify women most at risk for greater and faster bone loss. When you lose bone, fragments of certain bone proteins appear in the urine; these are called N-telopeptides (NTx). A woman with more NTx protein fragments in her urine is likely to undergo bone loss more quickly and is thus at greater risk of excessive bone loss during menopause.

In the study, researchers looked at bone loss levels of NTx in about 500 early postmenopausal women, who were within 1 to 2 years of their last menstrual period. They found the following:
- The higher the NTx level in the urine, the faster the bone loss during menopause. This makes sense: a higher rate of bone breakdown would likely translate into greater bone loss.
- A urine NTx level above 65 nM BCE/mM Cr appeared to identify rapid bone losers reasonably well. To put this in context, the average premenopausal NTx level is 36 nM BCE/mM Cr, and I have generally found that postmenopausal women with a 50 NTx level lose ½ to 1% of bone mass per year.
- The association between early postmenopausal NTx and rate of bone loss was stronger at the spine than at the hip. This again makes sense because the spine is metabolically active trabecular bone, which typically loses mass years earlier than the hip.
- Furthermore, retrospectively, it was found that high urinary NTx in perimenopause was also associated with a higher rate of bone loss during the transition to menopause.
Bone loss in menopause is not evenly distributed over the ten-year menopause period (five years before a woman’s last menstrual period and five years afterward). Most bone loss occurs over a three-year period, starting 1 year before a woman’s last menstrual period and ending 2 years after her last menstrual period – known as ‘transmenopause’.

What does this research mean for you?

If you notice symptoms of perimenopause such as irregular periods and hot flashes, or if you have recently (within a few years) gone through menopause, a simple test of your NTx level in urine can help you identify a tendency toward excessive bone loss .

If you are experiencing excessive bone loss, you can take steps to find out why and correct the situation. When I work with individual clients, this is exactly the type of work I do with them.

More information about the simple urine test can be found in my short video and accompanying manual. You can also order this test online via our online request system with our laboratory partner Evexia.

And since you can’t really know when the year before your last period will occur until you actually have your last period, it’s a good idea to get started on a vigorous Better Bones program right away at the first signs of menstruation. perimenopause.

Reference:

Shieh A, et al. Urinary N-telopeptide and rate of bone loss during the transition from menopause to early post-menopause. J Bone Miner Res. 2016;31(11):2057-2064.

I am Dr. Susan E. Brown. I am a clinical nutritionist, medical anthropologist, writer and motivational coach speaker. Learn my proven 6-step natural approach to bone health in my online courses.
Source link
October 26, 2023
Breakthrough for ‘neglected’ rheumatic disease

Scientists have had success treating a ‘neglected’ inflammatory disease, polymyalgia rheumatica, with a drug that could offer patients an alternative to steroids.

The study, conducted by Anglia Ruskin University (ARU) and published in the New England Journal of Medicine, describes a successful trial of sarilumab. The drug, approved in Britain to treat rheumatoid arthritis, blocked the protein interleukin-6, which can cause inflammation.

Polymyalgia rheumatica (PMR) is characterized by pain and morning stiffness in the shoulder and hips and affects people over the age of 50. It can significantly affect quality of life and is currently mainly treated with the steroid glucocorticoids.

Although glucocorticoids can control the condition, more than half of PMR patients experience a relapse of their condition when they reduce their steroid medication. Interleukin-6 has been implicated in the pathophysiology of PMR because circulating elevated levels and increased tissue expression of interleukin-6 have been found in PMR patients.

During the year-long clinical trial conducted by researchers, 118 patients received either twice-monthly injections of sarilumab or a placebo. The sarilumab group received a tapering dose of glucocorticoid for 14 weeks in combination with bimonthly injections of sarilumab, while the placebo group received a tapering dose of glucocorticoid for 52 weeks.

The primary outcome at the end of the study was sustained remission of the condition. This happened in 28% of people taking sarilumab, compared to 10% of people taking the placebo. After achieving remission at 12 weeks, there were more disease flares in the placebo group (57%) compared to those who received sarilumab (24%).

Lead PMR expert and senior author of the study, Professor Bhaskar Dasgupta, from Anglia Ruskin University’s Medical Technology Research Center (ARU), said: “Polymyalgia rheumatica is a poorly managed and neglected condition for which current treatment is unsatisfactory and long time can take. Long-term side effects: Patients may experience relapses while tapering their medications, and very limited treatment options currently exist for these relapses.

“Our findings show promise that sarilumab can be used to treat PMR and improve outcomes for people coming off steroid medications.

“This is an exciting development that has the potential to improve treatment options for a condition common in older people. PMR is the most common reason for long-term steroid prescriptions. Any effective drug that can spare the use of steroids would be a should have a major impact.” on reducing the serious side effects of such steroids, including diabetes, osteoporotic fractures and infections.”

The research was funded by Sanofi and Regeneron Pharmaceuticals.

Source link

October 26, 2023
Antidepressants, osteoporosis and psychiatry: Dr.Aruna Tummala

Can your antidepressants, especially SSRIsbe a hidden culprit behind it weakening of bones and osteoporosisespecially when you are navigating postmenopause?

What is it exactly “holistic psychiatry”, and how could it revolutionize your understanding of mental health?

Want to know which of your favorite foods are silent undermining your bones and mental clarity?

Dive into this episode for answers!

I had an eye-opening conversation with Dr. AS The words of the Tummala, a board-certified adult, geriatric and holistic psychiatrist. We’ve peeled back the layers on the rarely discussed connections between them diet, trauma, toxins, and their potential to impact both your mental health and your bone health.

Episode timeline

0:00 – Episode begins

1:28 – Introduction to Dr. Aruna Tummala

2:53 – The link between osteopenia, osteoporosis, bone loss and mood disorders in postmenopausal women. The risks of antidepressants, especially SSRIs, in increasing bone loss and fracture risk

6:05 – Insight into holistic psychiatry and Dr.’s journey Tummala to become a holistic psychiatrist

12:14 – Exploring common misconceptions and practices surrounding nutrition as a contributor to mental health

18:12 – Exploring the profound effects of trauma on mental health

24:55 – The role of family in healing trauma

27:32 – Analysis of the role of environmental toxins in mental health problems

32:22 – Dietary approaches and their effectiveness in treating various mental health conditions.

34:57 – The importance of whole foods, consuming organ meats for better brain and bone health, and the shift in dietary habits across generations

40:59 – Key insights for the audience

42:47 – Introduction and brief overview of Dr.’s upcoming book. Tummala, “Psychiatry 2.0.”

44:05 – Where to find Dr. The words of the Tummala

Sources mentioned

**Show notes @ https://bonecoach.com/aruna-tummala-psychiatry2-trinergyhealth-antidepressants-osteoporosis

Below you will find resources from Dr. Aruna Tummala!

>> Visit Dr.’s main website Aruna
>> Read more about Dr.’s Psychiatry 2.0 program. Aruna
>> Follow Dr. Aruna on Facebook
>> Follow Dr. Aruna on Twitter
>> Follow Dr. Aruna on Instagram
>> Follow Dr. Aruna on Tiktok
>> Connect with Dr. Aruna on Linkedin

What can you do to support your bone health and this podcast?

1. Press the “Subscribe” button on your respective podcast player (i.e. Apple, Google, Spotify, Stitcher, iHeart Radio and TuneIn). Never miss an episode that can help improve your bone health.

2. Leave a review. The more positive ratings and reviews and the more subscribers we have, the more people can find us and get the answers to the questions they need. Thank you! 🙂

3. Tell a friend about The Bone Coach Podcast or share via text, email or social. Do you know of a Facebook group where people can benefit from this information? Feel free to click any of the share buttons below.

About Dr. Aruna Tummala, MD:

Dr. Aruna Tummala is a certified adult, geriatric and holistic psychiatrist; and founder of Trinergy Health in Wisconsin, USA. Dr. Aruna provides evidence-based, holistic solutions for mental and whole-body wellness so you can achieve health, harmony and vitality… naturally!

Considered a pioneer in the field of holistic psychiatry, Dr. Aruna’s signature program, Psychiatry 2.0 – a unique, root cause method to treat mental health issues by first healing the body, then healing the mind. Psychiatry 2.0 combines the age-old wisdom of Ayurveda with functional medicine to find and address the root causes of a patient’s psychophysiological symptoms. This program can be offered in person or online as mental health coaching, allowing Dr. Aruna can serve clients all over the US and the world!

She offers a wide range of interventions including diet, exercise, meditation, yoga, nutritional supplements, Ayurvedic herbs, HBOT, psychotherapy, and so on. With this method, patients’ symptoms improve and their diseases are also eradicated from the root. Her approach reduces dependence on psychiatric medications, thereby reducing the severity and occurrence of side effects, while empowering her patients to take charge of their health!

She is passionate about empowering you through education and self-awareness so you can achieve your best, healthiest, most vibrant, inspired self.

Medical disclaimer

The information shared above is for informational purposes only and is not intended as medical or nutritional therapy advice; it does not diagnose, treat or cure any disease or condition; it should not be used as a substitute or substitute for medical advice from physicians and trained medical professionals. If you are under the care of a healthcare professional or are currently taking prescription medications, you should discuss any changes in your diet and lifestyle or possible use of nutritional supplements with your doctor. You should not stop prescribed medications without first consulting your doctor.

Source link

October 26, 2023
Ginger shows promise as a natural defense against autoimmune diseases
This is evident from a recent study published in the journal JCI Insight, the authors built on their previous work examining the anti-autoimmune disease effects of 6-gingerol, the most abundant phytochemical produced by the roots of the ginger herb. Because their previous work showed that this plant extract could reverse the effects of neutrophil hyperactivity in mouse model systems, the researchers herein evaluated whether oral consumption of whole ginger extracts could have similar effects both in mouse models and in human pilot trials. Their results show that ginger consumption for just seven days neutralizes hyperactivity in neutrophils in both in vivo systems. When taken by healthy individuals, it increases their resistance to developing conditions, including lupus and antiphospholipid syndrome (APS).

Study: Ginger intake suppresses extracellular neutrophil formation in autoimmune mice and healthy humans. Image credits: Nataly Studio / Shutterstock

Neutrophilic autoimmune diseases and the untapped potential of herbs

Antiphospholipid antibody syndrome (APS) is an autoimmune disease that mainly affects women between the ages of 30 and 40. APS results in the formation of abnormal proteins that promote clot formation in veins and arteries and is especially harmful to both mother and her fetus during pregnancy. APS and lupus, a frequent comorbidity characterized by circulating immune complexes that damage organs after their deposition, are lifelong, incurable conditions resulting from genetics, environmental exposure, or a combination of these. Both diseases result in significant mortality, morbidity and healthcare costs.

Previous research has shown that, despite having very different clinical profiles, both APS and lupus are pathologically caused by the exaggerated and abnormal formation of extracellular neutrophils, medically termed ‘NETosis’. During NETosis, neutrophils overexpress and secrete their nuclear chromatin in the form of web-like structures with pro-inflammatory properties and potentially harmful granule-derived proteins that, despite being localized in organs and the circulatory system, have serious consequences on the health.

Recent studies have shown that excessive NETosis, in addition to its own negative consequences, can result in sustained formation of autoantibodies, resulting in other autoimmune diseases that would otherwise have been suppressed by the body’s adaptive immune tolerance. Considering that most of these autoimmune diseases are incurable, require constant and usually expensive medical interventions, and carry significant mortality costs, finding a low-cost therapy for NETosis is imperative.

In recent years, scientific attention has shifted to the potential of herb-derived phytochemicals with anti-inflammatory properties as a wealth of safe and natural remedies against autoimmune diseases in general, and NETosis in particular. In a previous study, the authors of the current work showed that a purified ginger extract, 6-gingerol, shows promise in stimulating intracellular cyclic adenosine monophosphate (cAMP) and attenuating neutrophil phosphodiesterase (PDE) activity, both of which are important mechanistic results are from NETose.

In particular, their research found that NETs and neutrophils in manifestations of thromboinflammatory diseases not only influence APS, lupus and similar autoimmune diseases, but also promote adverse outcomes in communicable diseases such as coronavirus disease 2019 (COVID-19).

About the study

The current study aimed to determine whether whole ginger extracts have similar NETosis-reversing effects as 6-gingerol and have beneficial effects on consumption even for healthy individuals who do not exhibit autoimmune symptoms. This study represents a pilot study that may form the basis for future clinical testing of ginger’s beneficial proteins in the treatment of a spectrum of NETosis-related autoimmune diseases, including APS, lupus, vasculitis, rheumatoid arthritis, and even COVID-19.

Researchers began testing the efficacy of powdered whole ginger obtained from Aurea Biolabs (Kerala, India) in in vitro testing. Immunoglobulin G (IgG) was obtained from both APS and lupus patients (cases) and healthy controls and purified using the Protein G Agarose Kit (Pierce). The purity and concentration of IgG were estimated using Coomassie staining and BCA protein assay, respectively. For NETosis assays in human neutrophils, blood was collected from healthy human volunteers, purified via density gradient centrifugation, and neutrophils were isolated using dextran sedimentation and red blood cell (RBC) lysis. Flow cytometry and nuclear morphology microscopy were used to verify purity.

For NETosis assays, the above purified neutrophils were mixed with neutrophils derived from APS and lupus patients (three volunteers, respectively). In vitro assays consisting of immunofluorescence microscopy, measurements of phosphodiesterase (PDE) activity, and calculations of intracellular cAMP levels.

In vivo APS models included venous thrombosis experiments performed on male C57BL/6 mice (10-13 weeks). Female BALB/c mice (9 weeks old) were used for lupus testing. The venous thrombosis testing was performed using an electrolytic inferior vena cava (IVC) model. Circulating myeloperoxidase (MPO)-DNA complexes were then quantified and isolated thrombi were processed via thrombus section and immunohistochemistry.

Finally, the pilot study was conducted in humans. Participants older than 18 years and without NETosis-associated autoimmune diseases were recruited. Female participants had to be fertile to allow the evaluation of ginger consumption in combination with contraception. Women who were pregnant, lactating, or suffering from cardiovascular disease, diabetes, or cancer were excluded to avoid confusion due to their illness or the medications they were taking. All statistics performed in this study were 1-way analysis of variance (ANOVA) corrections based on multiple corrections.

Findings of the study

The main findings of this study were that ginger consumption significantly inhibited NETosis in healthy study participants, even after stimulation (mixing) of neutrophils from APS or lupus patients. This was expected given that their previous research reported the same findings on the use of purified 6-gingerol supplementation, and whole ginger extracts contained approximately 20% 6-gingerol. Similarly, this study presents that consumption of whole ginger inhibited cAMP-specific PDE activity, confirming previous findings.

In in vivo mouse models, consumption of whole ginger APS was shown to attenuate IgG-mediated venous thrombosis and NETosis. Remarkably, consumption of whole ginger attenuates lupus-relevant disease activity even in lupus-positive female BALB/c mice.

Pilot human experiments confirm that ginger is an important focus in future clinical trials, as it was found to stimulate neutrophil cAMP and reduce NETosis in healthy human volunteers, even after just seven days of ginger diet supplementation. To verify these results and confirm that the findings were not a byproduct of the small sample size (N = 9; 3 men, 6 women), the study was repeated with an unrelated volunteer cohort (N = 8). findings consistent across replications. Furthermore, the second cohort study revealed a reduction in plasma NET levels (measured by the MPO-DNA complexes).

Conclusion

The current study highlights the potential of whole ginger consumption as a safe and natural intervention, both to treat existing cases of APS, lupus and other NETosis-associated diseases and to prevent the development of these conditions in previously healthy people . They combined in vitro testing with in vivo mouse and human models and found that consumption of whole ginger attenuates venous thrombosis (APS) and significantly reduces the clinical features of lupus in mouse models.

In healthy human volunteers, ginger consumption for just seven days was associated with a notable reduction in NETosis and cAMP, confirming its potential against autoimmune diseases in future clinical trials.

“…we found that the dissolved ginger extract counteracted the PDE activity of neutrophils. The result was increased neutrophil intracellular cAMP levels, which were associated with blunted NETosis by human neutrophils in vitro. Such data complement recent studies that have reported a role for ginger extracts, and in particular 6-gingerol, as inhibitors of cAMP-specific PDE activity. Importantly, the suppressive effects of ginger on NETosis can be attenuated by blocking PKA activity, a key downstream cAMP-dependent kinase. The fact that increasing neutrophil cAMP and activating PKA would be beneficial for disease activity in mice is in good agreement with our previous work demonstrating the potential therapeutic target of this pathway in APS and lupus models with synthetic PDE4 inhibitors. ”
Magazine reference:

Ramadan A. Ali, Valerie C. Minarchick, Miela Zahavi, Christine E. Rysenga, Kristin A. Sturm, Claire K. Hoy, Cyrus Sarosh, Jason S. Knight, M. Kristen Demoruelle. Ginger intake suppresses extracellular neutrophil formation in autoimmune mice and healthy humans. JCI Insight. 2023;8(18):e172011, DOI – https://doi.org/10.1172/jci.insight.172011, https://insight.jci.org/articles/view/172011
Source link
October 26, 2023
Best Bone Health Supplements with Cr. McCormick

Hello friends of bones:

I am pleased to present my interview on bone supplements with Dr. McCormick. We discussed his full line of bone supplements that are a key ingredient for healthy bones and why calcium in lower doses is important.

A number of attendees indicated that they could not participate in the zoom call.

My 2022 gift to my community is the recording and transcript.

Keep in mind that:

I am not affiliated with Dr.’s supplements. McCormick. I find good bone loving products and bring them to my community. I broke the marketing hype. I’m currently taking his Mineral Whey and his Collagen. My bones are strong.

Like Dr. McCormick said, supplements are just that; they supplement our food. They do not take the place of food. This is an important part of bone health; food. Calcium and mineral rich nutrition that I provide in my private sessions and my monthly membership Bones Tribe.

Dr. McCormick is one of dozens of doctors to whom I refer my clients. I have a team. My work has grown significantly and I am able to help more clients understand their diagnosis, bone markers and blood work. And find the right bone doctor, functional colon doctor and serve as an advocate during private conversations with their doctors.

A few of my referral physicians are: Dr. McCormick, D.C., Dr. Lani Simpson, DC, CCD Certified Densitomitrist, Dr. Paul Miller, Dr. Jessica Starr, HSS Dr. Aly Cohen, Integrative Rheumatologist, Dr. Lorraine Maita, Dr. Deva Boone, Parathyroid Surgeon, Dr. Kim Zamito, Orthopedic Surgeon offering Echolight and Functional and Integrative Physicians: Dr. Kristann Heinz, RD, Dr. Adi Benito.

I have also found DXA/TBS facilities for my clients across the country.

Highlights:

**Dr. McCormick developed severe osteoporosis at the age of 45. He suffered 22 fractures during his 5-year bone journey. He was on bone medications (Forteo and Fosamax) for a few years. It is fracture free and continues to run long distances.

**Dr.’s OsteoSustain supplement McCormick contains 500 mg of calcium. He uses 4 different types of calcium, dicalcium malate, calcium citrate nitrate, calcium bis-glycinate chelate, calcium ascorbate.

**The rest must come from food

**All of its supplements can be taken together:

OsteoSustain, OsteoStim, Mineral Whey and Collagen

**His Mineral Whey comes from goats that have not been exposed to pesticides, herbicides, antibiotics or growth hormones. Often those who are bothered by dairy do not respond to goat’s milk.

**Gluten intolerance/celiac disease plays a major role in bone health.

**Dr. McCormick mentioned Echolight. This new procedure is making its way into the world of bone health.

**Vitamin K2/MK-4 is important for bone health.

** 500-1000 micrograms K2/MK-4. OsteoStim has 700 micrograms and OsteoSustain has 100 micrograms, for a total of 800 micrograms.

**K2/MK-7 has a longer half-life. Osteostim has 50 micrograms.

**Those diagnosed with osteopenia should monitor your CTx

**High CTx anything above 400 is high.

**An osteoporosis patient reported that she significantly lowered her CTx using Dr. McCormick to use

**Always test your vitamin D levels. Dr.’s reach McCormick is 30-50 ng/ml. I test my levels twice a year. At the end of summer and during the winter months.

You can take supplements from Dr. Buy McCormick HERE

Enjoy the recording below.

Would you rather read the transcript? Scroll down past my signature.

Do you already know you want to work with my team?

It is best to start with a comprehensive private session where a plan is designed specifically for you and your bones. Private sessions cost $200, including full session notes.

Let me support your bones

Receive an in-depth, tailor-made private session

Book a private coaching with Irma now

Join our amazing Bone Tribe community

Get the support and information you need to live fearlessly with your bone diagnosis

From my bones to yours….welcoming 2022.

Irma Jennings, INHC

Your holistic bot coach

[email protected]

Source link

October 26, 2023
Bone stress injuries in cross-country running on athletic training services

Epidemiology of bone stress injuries and health care utilization among PAC-12 athletes across the country

[ PMC gratis artikel ][ PubMed ]Wayner RA, Brown CN, Bovbjerg VE, Fredericson M, Soucy MT, Choe S, Simon JE. J Athl train. 2023;10.4085/1062-6050-0089.23 [published online ahead of print, 2023 Jul 18].

Full text freely available

Take home message

Bone stress injuries in cross-country athletes are most common in women, are excessively stressful, and require 10 to 11 shifts of athletic trainers.

Background

The injury rate in cross country running is approximately 4 per 1000 athletic exposures. Some authors have found that bone strain injuries account for ~20% of all injuries nationwide. Patients who sustain a bone strain injury may be at up to six times greater risk for subsequent bone strain injury. Unfortunately, we know little about how common bone stress injuries occur in male and female NCAA Division I cross country athletes and what health care services they receive.

Study objectives

The authors assessed health care utilization, injury rates, and injury characteristics of bone stress injuries in NCAA Division I cross country athletes.

Methods

The authors used deidentified data from the PAC-12 Health Analytics Program injury registry. The registry included data on injuries and health care services entered by athletic trainers from July 2018 to June 2022. The authors classified bone strain injuries as injuries in the lumbar spine, pelvis, or lower extremities. For this article, they excluded cases of medial tibial stress syndrome. The authors categorized injuries into acute or chronic onset and time-loss or non-time-loss injuries. They then calculated health care utilization by counting the number of encounters with a health care provider (athletic trainer or doctor), prescriptions, procedures, or tests. The authors also assessed the time of year the injury occurred: pre-season, during-season, post-season, and off-season.

Results

The number of bone stress injuries was 0.14 per athlete season. The rate of bone stress injury in women was 58% higher than in men. Overall, 92% of bone strain injuries occurred through an overuse mechanism. More specifically, 73% of all bone stress injuries had time loss and overuse classifications. On average, a patient received 10.5 athletic training services. Patients with an overuse and time-loss injury tended to receive slightly more athletic training services than patients with an overuse and non-time-loss injury (10.9 versus 12.2).

Viewpoints

Among Division I collegiate cross country runners, bone stress injuries are common and are usually caused by overuse mechanisms, leading to lost time. These injuries required significant athletic training services, but rarely other health care services (e.g., medications, tests, procedures, surgeries). It would be interesting to see if this pattern continues in other athletic conferences. The authors recognized that the use of athletic training services among these collegiate patients was more important than the use of athletic training services among high school cross country runners. Therefore, we need to carefully apply these results to different age groups.

Clinical implications

Clinicians should promote injury prevention programs for cross country athletes that target overuse injuries, including bone stress injuries. The high demand for athletic training services for this patient population highlights the need for adequate staffing to work with collegiate Division I cross-country skiers.

Related posts

Is lifestyle a factor for adolescents with bone stress injuries?
Who Gets Stress Fractures in College?

Written by Mitchell Barnhart
Reviewed by Jeffrey Driban

Source link

October 26, 2023
Dr. Abbasi from Inspired Spine brings OLLIF’s expertise to Orlando, where he meets Dr. Jose Jimenez-Almonte trains

Inspired Spine CMO Dr. Hamid Abbasi performs one of more than 1,500 OLLIF procedures

BURNSVILLE, Minn., Oct. 25, 2023 /PRNewswire/ — Inspired Spine, a leader in innovative minimally invasive spine surgery, is pleased to announce that Dr. Abbasi, a renowned pioneer in the field of orthopedic and neurosurgery, will travel to Orlando, Florida to share his expertise in the revolutionary Oblique Lateral. Lumbar Interbody Fusion (OLLIF) Procedure for Dr. Jose Jimenez-Almonte.

Dr. A leading figure in the world of minimally invasive spine surgery, Abbasi is known for his groundbreaking contributions in the field. His OLLIF procedure has not only improved patient outcomes, but also dramatically shortened recovery times, making it a preferred choice for patients seeking relief from debilitating back pain.

The OLLIF procedure offers a minimally invasive alternative to traditional open spinal fusion, allowing patients to regain their quality of life faster with less pain and less scarring. Dr. Abbasi’s commitment to advancing this field has made him a sought-after teacher and mentor to many surgeons in the United States.

Inspired Spine is pleased to facilitate this unique opportunity for Dr. Jose Jimenez-Almonte, an esteemed spine surgeon in Central Florida. The dedication of Dr. Jimenez-Almonte’s commitment to offering its patients advanced spine surgery options aligns perfectly with Inspired Spine’s mission to advance minimally invasive spine surgery techniques.

The Proctorship offers Dr. Jimenez-Almonte an exclusive opportunity to hear directly from Dr. Abbasi, who will share his insights, techniques and 10 years of experience in the OLLIF procedure. The collaboration reflects Inspired Spine’s commitment to advancing excellence in minimally invasive spine surgery, further expanding access to innovative treatments for patients in Orlando and beyond.

“We are thrilled to bring together two exceptional medical professionals for this event,” said Amanda Armagost, a representative of Inspired Spine. “Dr. Abbasi’s mastery of the OLLIF procedure, coupled with the expertise and dedication of Dr. Jimenez-Almonte, holds great promise for the advancement of minimally invasive spine surgery in the Orlando area.”

This collaboration is an example of Inspired Spine’s commitment to advancing the field of minimally invasive spine surgery and making advanced treatment options more widely available, ultimately benefiting patients with debilitating spine conditions.

For media inquiries or for more information about Inspired Spine and this exciting event, please contact Amanda Armagost at aarmagost@islife.us

Inspired Spine is a leader in the development and promotion of minimally invasive techniques for spine surgery, with a strong focus on the OLLIF procedure. Their commitment to innovation and collaboration with leading surgeons such as Dr. Abbasi allows them to provide patients with advanced treatments that provide faster recovery and a better quality of life. Inspired Spine continues to lead the way in advancing minimally invasive spine surgery.

SOURCE Inspired Spine

Source link

October 26, 2023
Largest study ever further confirms the power of exercise to improve mental health

A new meta-analysis has pooled results from 97 reviews and provides an in-depth perspective on the profound impact of physical activity on mental well-being.

The study is considered the most comprehensive meta-analysis on the subject to date and underlines the undeniable benefits of exercise as a powerful remedy against psychological problems, surpassing the effects of traditional psychotherapy and pharmacotherapy in certain aspects.

Let’s dig deeper into the specifics of this research so you can reap the dual benefits of better mental health and better bone health through physical activity.

Deciphering the meta-review on exercise and mental health

This meta-review, published in the British Journal of Sports Medicine, rigorously evaluated and ranked the outcomes of previously conducted systematic reviews. Each of these systematic reviews in turn integrated the results of numerous individual studies.

In total, this meta-review includes 97 reviews, covering 1039 studies with no fewer than 128,119 participants. These participants ranged from healthy adults and individuals struggling with mental health issues, to those with various physical conditions.

The studies in this meta-review used a variety of physical activity interventions and assessed their impact on depression, anxiety and psychological distress. The primary objective was to distinguish the effectiveness of these interventions in reducing mental health problems.¹

Short content

The meta-review integrated findings from 1,039 studies involving 128,119 participants, focusing on the role of physical activity in addressing mental health issues.

The healing power of physical activity

This meta-review conclusively establishes that physical activity (PA) serves as a powerful antidote for relieving mild to moderate symptoms of depression, anxiety, and psychological distress. In fact, the reduction in symptoms of depression (-0.43) and anxiety (-0.42) resulting from physical activity was comparable to, or even slightly better than, the effects observed with psychotherapy and pharmacotherapy.

Although previous research has shown that physical activity can rival the benefits of psychotherapy and medicinal treatments for depression, anxiety and mental health problems, its limited scope often leaves medical professionals skeptical.¹ However, this comprehensive meta-review includes a diverse demographic and a spectrum of physical activities.

Interestingly, the research revealed that all forms of physical activity were effective, whether aerobic, resistance-based, mixed or yoga, were beneficial. The study found that all forms of physical activity were beneficial, including aerobics, resistance exercises, mixed exercises and yoga. Resistance exercises in particular showed the most pronounced positive effects on depression, while yoga emerged as the most powerful anti-anxiety tool.¹

Incorporating a wide variety of exercises into your workout regimen can provide a plethora of health benefits. Surprisingly, shorter exercise sessions proved to be more effective than longer interventions, likely due to higher adherence, highlighting the importance of cultivating an enjoyable and sustainable exercise routine.

Short content

Physical activity has been validated as a valuable tool for improving mental health, with different exercises offering unique benefits. The effects on depression and anxiety are comparable to or even slightly better than those of traditional therapeutic methods.

The symbiotic relationship between mental health and bone health

Exercise is crucial for promoting robust bone health. The physical stress on the bones due to exercise stimulates the bone formation process, leading to the development of stronger, healthier and younger bones.

This study highlights another dimension of exercise’s protective role: its ability to boost mental health.
Increased stress levels, often due to anxiety and other mental health issues, lead to an increase in the stress hormone cortisol. Excessive cortisol can be harmful to bone health.

Additionally, a healthy mental state facilitates the consistent pursuit of other health goals, such as maintaining a healthy diet and ensuring adequate sleep. This study highlights how exercise can help you maintain good mental health, which in turn supports your other healthy habits, including exercise!

Short content

Exercise not only strengthens bones directly, but also protects them indirectly by improving mental health, reducing stress-induced bone damage and promoting health habits.

What this means for you

The essence of this meta-analysis is clear: physical activity is a panacea for mental well-being. The key is to stay active without getting caught up in the intricacies of the ‘perfect’ workout.

Building an enjoyable and sustainable exercise habit can be intimidating at first – that’s why the Save Institute created SaveTrainer. SaveTrainer offers you the most effective training.

For those seeking guidance, SaveTrainer offers a curated collection of workouts tailored for every skill level, duration, body part and health goal. SaveTrainer has a wide range of classes for bone strength, joint health, balance, posture, flexibility, meditation, sleep improvement and yoga.

SaveTrainer keeps you active, happy and healthy.

References

¹ https://bjsm.bmj.com/content/early/2023/03/02/bjsports-2022-106195

Source link

October 26, 2023